Grail Analyst Sees Massive Market Potential with Valuation Headwinds

Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100

Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price target from $65 to $100.

FDA Panel Endorses GRAIL Galleri Cancer Screening Tool

The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use

https://www.fda.gov/media/194909/download

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript

On Thursday, Illumina (NASDAQ:ILMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data